Home / Mumbai / Mumbai News / Article /
Mumbai: Amid shortage of Tocilizumab, experts question its efficacy
Updated On: 20 August, 2020 07:00 AM IST | Mumbai | Arita Sarkar
As patients kin scramble from one pharmacy to another looking for Tocilizumab, COVID task force says it has limited effect; recommends Itolizumab, a similar drug believed to be more effective, economical

Health workers conduct tests in Kurla on Wednesday. Pics/Sayyed Sameer Abedi
Amidst a shortage of Tocilizumab, a drug considered to be one of the supportive treatments for COVID-19, experts have started to question its efficacy. While relatives of patients are extremely worried about its unavailability, members of the COVID task force and doctors feel that Tocilizumab has limited effects and Itolizumab, a similar drug, priced at one-fourth the former, is more effective.
Speaking to mid-day, Dr Om Srivastava, infectious diseases specialist and member of the COVID task force, said that he had seen positive results in 20 patients he administered Itolizumab to. "It is a far more effective option. While Tocilizumab has a unimolecular directional approach, Itolizumab has consistent effects on several sites at the same time," he said.


